| Title | Phase I/II Study of PHY906/Capecitabine in Advanced Hepatocellular Carcinoma. | | Author(s) | Yen Y, So S, Rose M, Saif MW, Chu E, Liu SH, Foo A, Jiang Z, Su T, Cheng YC | | Institution | FACP, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010-3000, USA. yyen@coh.org. | | Source | Anticancer Res 2009 Oct; 29(10):4083-92. | | Abstract | PHY906 is a Chinese medicine formula with claims for the treatment of severe gastrointestinal distress. PHY906 enhanced the therapeutic index of various chemotherapeutic agents in human hepatocellular carcinoma xenografts. Accordingly, here a phase I/II clinical study was conducted with the combination of capecitabine in patients with advanced, unresectable hepatocellular carcinoma. More than 60% of patients had either stable disease or better after two treatment cycles. Median overall survival was 9.2 months. Asian patients had a higher median overall survival (16.5 months) than non-Asian patients (6.2 months, p=0.03). Patients' quality of life did not deteriorate significantly during treatment. This finding supported further investigation of PHY906 as an adjuvant therapy of capecitabine in a larger hepatocellular cancer population. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19846955 |
|
